Lavinia

Ethinylestradiol and Levonorgestrel, the active ingredients in Lavinia, are a combined oral contraceptive presented as tablets for oral use. They prevent pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Lavinia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Lavinia, a combined oral contraceptive, is used in the hormonal regulation of reproductive health.

Contraception: Prevents pregnancy by suppressing ovulation and modifying cervical mucus. Menstrual cycle regulation: Provides more predictable bleeding patterns and reduces cycle length variability. Dysmenorrhea relief: Decreases menstrual pain through hormonal stabilization. Acne management: Lowers androgen‑driven skin lesions in women.

Like all hormonal contraceptives, Lavinia may cause a range of adverse reactions.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting between periods - Weight gain - Mood changes

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Stroke or myocardial infarction - Severe allergic reaction (anaphylaxis)

Before prescribing Lavinia, clinicians should consider several safety aspects.

Assess thrombotic risk: avoid in women with a history of blood clots or clotting disorders. Review cardiovascular health: contraindicated in smokers over 35 and those with uncontrolled hypertension. Evaluate liver function: use with caution in hepatic impairment. Consider drug interactions: check concomitant use of enzyme‑inducing medications. Counsel on pregnancy: product is contraindicated during pregnancy (Category X). Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lavinia can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antiepileptics such as carbamazepine or phenytoin, which may reduce contraceptive efficacy. - Rifampicin and other strong enzyme inducers, significantly lowering hormone levels. - Certain HIV protease inhibitors, increasing risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole) that may increase hormone concentrations. - Some antibiotics (e.g., tetracycline) with a possible slight reduction in effectiveness. - St. John’s Wort, which may modestly decrease the contraceptive effect.